Familial Hypercholesterolemia Clinical Trial
Official title:
Hellenic Registry for Familial Hypercholesterolemia
Familial hypercholesterolemia (FH) [heterozygous (heFH) or homozygous FH (hoFH)] is a common genetic disorder, characterized by elevated plasma low density lipoprotein (LDL) cholesterol concentration leading (if untreated) to cholesterol deposits in the corneas, eyelids and extensor tendons, rapidly progressing vascular disease, and aortic valve disease.
In contrast, timely recognition and effective treatment of FH can result in a significant
improvement in clinical outcomes. The problem is that that majority of individuals with FH
are unaware of their disease, particularly that the disease remains silent for many years. In
most countries around the world <5% of individuals with FH are identified .
Until lately the prevalence of heFH was traditionally considered to be ~ 1:500 individuals ,
although clinical and genetic studies suggest that heFH affects ~ 1:200-250 individuals .
Thus, the aim of the Hellenic College of Treatment of Atherosclerosis (HCAT) is to 1).
Evaluate the prevalence of FH in Greece (FHG-Registry) and 2). To inform population of FH
disease.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT05284513 -
Collaborative Approach to Reach Everyone With Familial Hypercholesterolemia (CARE-FH)
|
N/A | |
| Enrolling by invitation |
NCT05271305 -
Pilot Study for a National Screening for Familial Hypercholesterolemia
|
||
| Completed |
NCT02750527 -
Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
|
||
| Not yet recruiting |
NCT00924339 -
Soy Food Intervention Trial
|
N/A | |
| Withdrawn |
NCT00751608 -
Effect of APL180 on Endothelial Function in Familial Hypercholesterolemia Patients
|
Phase 2 | |
| Terminated |
NCT00079846 -
Implitapide in Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Maximal Concurrent Lipid-Lowering Therapy
|
Phase 2 | |
| Completed |
NCT02624869 -
Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)
|
Phase 3 | |
| Recruiting |
NCT05758779 -
The Danish Familial Hypercholesterolemia Organized Coronary Screening Trial
|
N/A | |
| Enrolling by invitation |
NCT04929457 -
Evaluation of a Digiphysical Screening Method to Identify and Diagnose Familial Hypercholesterolemia
|
||
| Not yet recruiting |
NCT04455581 -
A Study to Determine the Safety, Tolerability, and Efficacy of SHR-1209 in Patients With Familial Hypercholesterolemia
|
Phase 2 | |
| Recruiting |
NCT04101149 -
Genetic Causes of Familial Hypercholesterolemia
|
||
| Completed |
NCT00943306 -
Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia
|
Phase 3 | |
| Completed |
NCT02462655 -
Effects of LDL Apheresis System on the Expression of Genes Involved in Lipoprotein Metabolism and Inflammation in Homozygotes for Familial Hypercholesterolemia
|
N/A | |
| Terminated |
NCT00079859 -
Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy
|
Phase 2 | |
| Recruiting |
NCT05066932 -
Advanced Lipoproptein Profiling and Cardiovascular Risk Stratification in Familial Hypercholesterolemia
|
||
| Not yet recruiting |
NCT04958629 -
A Prospective Cohort Study on Familial Hypercholesterolemia in Health Examination Population
|
||
| Completed |
NCT02709850 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia
|
Phase 1 | |
| Active, not recruiting |
NCT03832985 -
Pediatric Reporting of Adult-Onset Genomic Results
|
Early Phase 1 | |
| Terminated |
NCT02013713 -
French Observatory of Familial Hypercholesterolemia in Cardiology
|
||
| Recruiting |
NCT02009345 -
Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada
|